These findings suggest that type I PRMT inhibition may indirectly affect the EGFR-RAS-MAPK signaling axis via lysosomal hydrolase activity, ultimately influencing lysosomal exocytosis and drug sensitivity in cancer cells. Here, EGFR is linked to cancer.